A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps
机构：[a]Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China首都医科大学附属北京同仁医院临床科室耳鼻咽喉-头颈外科变态反应科[b]Department of Otolaryngology Head and Neck Surgery, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China[c]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of Education of China) of Capital Medical University, Beijing 100005, China首都医科大学附属北京同仁医院研究所耳鼻咽喉科研究所[d]Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, 9000 Ghent, Belgium[e]Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing 10073, China首都医科大学附属北京同仁医院临床科室内分泌科[f]Departments of Oncology, Community Health Sciences, and Surgery, Cumming School of Medicine, and The Center for Health Informatics, University of Calgary, Calgary, Alberta, Canada[g]MIID Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada[h]Department of Epidemiology research, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China[i]Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital of Münster, Münster, Germany[j]Department of Otorhinolaryngology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China中山大学附属第一医院
Little evidence exists regarding an integrated multidimensional evaluation methodology to analyze the within-patient effects of medical treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). We aimed to use an integrated evaluation model to analyze the effects of short-course oral corticosteroid (OCS) followed by intranasal corticosteroid spray (INCS) therapy in patients with severe CRSwNP.In all, 32 patients with severe CRSwNP received oral methylprednisolone for three weeks followed by intranasal budesonide spray for nine weeks in this prospective single-arm study. An evaluation model integrating the concepts of the core outcome set (COS), clinical control and minimum clinically important difference (MCID) was longitudinally evaluated.All uncontrolled patients at baseline showed similar progressive improvements from baseline and more than 1 MCID response across core outcomes during the OCS period, with severe CRSwNP being partly controlled in 31 (96.9%) patients and uncontrolled in 1 (3.1%) patient at 3 weeks. During the subsequent INCS period, 14 (43.8%) patients gradually deteriorated to an uncontrolled status at 12 weeks, whereas 18 (56.2%) exhibited partly controlled CRSwNP until 12 weeks.In more than half of the patients, severe CRSwNP was partly controlled with the initial OCS followed by INCS therapy. An integrated evaluation model was used to facilitate the comprehensive evaluation of within-patient response, especially in patients with different responses to the same treatment.ChiCTR1900024287.
基金：
National Key R&D Program of China
(2016YFC0905200); the program for the Changjiang scholars and innovative research team (IRT 13082); the National Natural Science Foundation of
China (81970852, 82000962 and 82171110); the Beijing Natural Science
Foundation (7222024); the CAMS Innovation Fund for Medical Sciences
(2019-I2M-5-022); the Beijing Municipal Science & Technology Commission
(Z211100002921057) ; the Capital’s Funds for Health Improvement and
Research (2022-1-1091); the Beijing Bai-Qian-Wan talent project (2019A32);
the Interdisciplinary cooperation project of Beijing Science and
Technology Star (20220484226); the Public Welfare Development and
Reform Pilot Project (2019-10); the National Science and Technology Major Project (2019ZX09201-005) and the High Level Public Health
Technical Talent Training Plan (Lingjunrencai-01-08, Lingjunrencai-02-09).
第一作者机构：[a]Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China[b]Department of Otolaryngology Head and Neck Surgery, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
共同第一作者：
通讯作者：
通讯机构：[a]Department of Otorhinolaryngology Head and Neck Surgery, Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100073, China[c]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases (Beijing Municipal Education Commission), Beijing Key Laboratory of Nasal diseases, Key Laboratory of Otolaryngology-Head and Neck Surgery (Ministry of Education of China) of Capital Medical University, Beijing 100005, China[*1]Department of Otolaryngology Head and Neck surgery and Department of Allergy, Beijing Tongren Hospital, Capital Medical University, No.1, Dong Jiao Min Xiang, Dong Cheng District, Beijing 100730, P.R. China[*2]Beijing Institute of Otolaryngology, No. 17, HouGou HuTong, Dong Cheng District, Beijing 100005, China
推荐引用方式(GB/T 7714)：
Shao Shan,Wang Yue,Zhang Nan,et al.A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps[J].EXPERT REVIEW OF CLINICAL IMMUNOLOGY.2023,doi:10.1080/1744666X.2023.2209724.
APA：
Shao Shan,Wang Yue,Zhang Nan,Zhao Yan,Zhang Xuelian...&Bachert Claus.(2023).A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps.EXPERT REVIEW OF CLINICAL IMMUNOLOGY,,
MLA：
Shao Shan,et al."A prospective single-arm study on the efficacy and safety of short-course oral corticosteroids followed by topical corticosteroids in patients with severe chronic rhinosinusitis with nasal polyps".EXPERT REVIEW OF CLINICAL IMMUNOLOGY .(2023)
：